Amin, Kamilia M.Taha, Aly M.George, Riham F.Mohamed, Nada M.Elsenduny, Fardous F.2019-11-092019-11-092018-01Cited References in Web of Science Core Collection: 370365-6233https://doi.org/10.1002/ardp.201700199https://www.ncbi.nlm.nih.gov/pubmed/29148081Accession Number: WOS:000419112800001A novel series of coumarin-thiadiazole heterocycle derivatives was synthesized by the nucleophilic substitution reaction. The synthesized compounds were structurally verified by IR, H-1 NMR, C-13 NMR, mass spectra, and elemental analyses. The antitumor activity of the synthesized compounds was evaluated through DNA binding assays and the 60-cell line panel according to the US NCI-DTP protocol or a selection of human tumor cell lines: breast cancer (MCF-7), liver cancer (HepG-2), and colorectal cancer (HCT-116). Most of the compounds had better DNA/ethidium bromide fluorescence quenching rather than methyl green displacement, suggesting superior DNA intercalation over DNA groove binding. Compounds 8 and 14b showed the best quenching effect with K-SV=4.27x10(5)M(-1). Moreover, the results for compounds 8, 4c, and 4e revealed a possible dual DNA binding mode with the intercalation to be superior, with K-SV 4.27x10(5), 3.96x10(5), and 3.51x10(5)M(-1), respectively, compared to 42%, 45%, and 43% methyl green displacement, respectively. Out of the 60-cell line panel, the leukemia HL-60 cell line was the most susceptible to growth inhibition when treated with 14a, resulting in 61% growth, followed by the lung carcinoma cell line NCI-H522 showing 67% growth when treated with 9. Moreover, compound 10c had an IC50 value of 24.9g/mL against the HepG-2 cell line.enantitumorcoumarinDNA bindingDNA cleavagethiadiazoleBIOLOGICAL EVALUATIONIN-VITRODERIVATIVESDESIGNCANCERPROLIFERATIONINHIBITIONESCULETINDOCKINGCELLSArticlehttps://doi.org/10.1002/ardp.201700199